Sun Pharmaceutical Industries Limited — Investor Meet, 05-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sun Pharma is acquiring Organon for an equity value of $3.99 billion ($11.75 billion enterprise value), funded by cash and debt. This aims for a $12.4 billion combined revenue and $2-2.5 billion annual free cash flow. Initial net debt/EBITDA will be 2.3x, with debt repayment a key focus.

Management sees growth from Organon's global reach, women's health, and biosimilar segments. Anticipated cost synergies are $350 million over 2-4 years, plus sales synergies. The deal is expected to be EPS accretive from year one. Management is confident in integrating and driving long-term value, applying lessons from past acquisitions for global expansion, notably in China.